Altimmune ALT announced that the FDA has granted Breakthrough Therapy Designation to its lead pipeline candidate, pemvidutide ...

"MetaVia OXM analogue agonist meets endpoints in Phase Ib weight loss trial" was originally created and published by Clinical ...

The first oral glucagon-like peptide-1 (GLP-1) drug has launched nationwide, marking a major expansion of access to the ...

Breakthrough Therapy Designation is intended to expedite the development and review of medicines that are intended to treat a serious or life-threatening condition and have shown preliminary clinical ...

The 2024 Lasker~DeBakey Clinical Medical Research Award has been given to Joel Habener and Svetlana Mojsov for their discovery of a new hormone GLP-1(7-37) and to Lotte Knudsen for her role in ...

Intravenous high‐dose glucagon is a recommended antidote against beta‐blocker poisonings, but clinical effects are unclear. We therefore investigated hemodynamic effects and safety of high‐dose ...

The next wave of obesity drugs is coming soon. Drug companies are racing to develop GLP-1 drugs following the blockbuster success of Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro and ...

Heart failure and cognitive impairment emerge as public health problems that need to be addressed due to the aging global population. The conditions that often coexist are strongly related to ...

Department of Clinical Pharmacology, , Bispebjerg Hospital, , University of Copenhagen, , Copenhagen, , Denmark Department of Clinical Medicine, , Faculty of Health ...

Baqsimi (glucagon) is a prescription drug that’s used to treat severely low blood sugar levels. The drug comes as nasal powder. It’s usually given as a one-time dose. Baqsimi is used in adults and ...